Portal de Periódicos da CAPES

Survival without Permanent Respiratory Support in a Patient with SMA Type 1 Treated with Nusinersen

2023; Volume: 8; Issue: 1 Linguagem: Inglês

10.29245/2572-9411/2023/1.1207

2572-9411

Micaela Pauni, Cecilia Mazzuzz, Guillermo Agosta,

RNA modifications and cancer

Spinal muscular atrophy (SMA) is a rare, but severe disease, which is characterized by progressive muscular weakness resulting in permanent assisted ventilation before the age of 2. Supportive care used to be the only available treatment. However, relevant progress has been achieved with the approval of nusinersen (an antisense oligonucleotide modulating SMN2 splicing), which changed the disease outcome for many patients. Thus, management of SMA patients requires a multidisciplinary approach with pharmacological and non-pharmacological treatments to provide the necessary supportive care for symptom management, nutritional support and active rehabilitation to optimize muscle function. In this paper we aimed to report the first patient with type 1 SMA in the Latin America region that was able to get off the ventilator without a tracheostomy after an early treatment with nusinersen, continuing to date stable and with no need of ventilatory support.